Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk guideline-based undertaking to improve dyslipidemia management in Canada (GUIDANC)

Canadian Journal of Cardiology

Volumn 27, Issue 2, 2011, Pages 138-145

  Katza, Pamela M ^a   Mendelsohnb, Aurora A ^b   Goodman, Shaun G ^a,b,c   Langer, Anatoly ^a,b,c   Teoh, Hwee ^c   Leiter, Lawrence A ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CANADIAN HEART RESEARCH CENTRE   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; ROSUVASTATIN; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ALGORITHM; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG TARGETING; DYSLIPIDEMIA; FEMALE; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; OBSERVATIONAL STUDY; PHYSICIAN; PRACTICE GUIDELINE; BLOOD; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

AGED; ALGORITHMS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CANADA; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79957993047     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2010.12.010     Document Type: Article

References (30)

1. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving lowdensity lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
3. Waters DD, Brotons C, Chiang CW, et al. Lipid Treatment Assessment Project 2:Amultinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120:28-34.
4. Saposnik G, Goodman SG, Leiter LA, et al. Applying the evidence: Do patients with stroke, coronary artery disease, or both achieve similar treatment goals? Stroke 2009;40:1417-24.
5. Hackam DG, Leiter LA, Yan AT, et al. Missed opportunities for secondary prevention of cardiovascular disease in Canada. Can J Cardiol 2007; 23:1124-30.
6. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006;119:676-83.
7. Banegas JR, Vegazo O, Serrano P, et al. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis 2006;188:420-4.
8. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in highrisk elderly patients: the treatment-risk paradox. JAMA 2004;291:1864-970.
9. Petrella RJ, Merikle E, Jones J. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Clin Ther 2007;29: 742-50.
10. Rapezzi C, Biagini E, Bellis P, et al. Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy. J Cardiovasc Med 2008; 9:878-87.
11. Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis 2007;191:135-46.
12. Baigent C, Landray M, Reith C, et al. for SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010;160(5):785-94.
13. SHARP: Study of Heart and Renal Protection Home Page. Available at: http://www.ctsu.ox.ac.uk/~sharp/. Accessed November 25, 2010.
14. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34.
15. Gagne C, Bays HE, Weiss SR, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.
16. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-24.
17. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24:717-28
18. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94.
19. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, doubleblind, placebo-controlled trial. Mayo Clin Proc 2004;79:620-9.
20. Feldman T, Koren M, Insull W, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III lowdensity lipoprotein cholesterol goals. Am J Cardiol 2004;93:1481-6.
21. Patel JV, Hughes EA. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolemia. Int J Clin Pract 2006;60:914-21.
22. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007;99:673-80.
23. Teoh H, Mendelsohn A, Goodman SG, et al. Usefulness of statinezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease. Am J Cardiol 2009;104:798-804.
24. Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J 2010;159:705-9.
25. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27.
26. Genest, J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations. Can J Cardiol 2009;25:567-79.
27. Genest J, Frohlich J, Fodor G, McPherson R Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: 2003 update. CMAJ 2003; 169:921-4.
28. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. NEJM 2009;360:1395-407.
29. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. NEJM 2005;353:238-48.
30. LaRosa JC, Grundy SM, Waters DD, et al. for Treating to New Targets (TNT) Investigators. Intensive lipid lowering with Atorvastatin in patients with stable coronary disease. NEJM 2005;352:1425-35.